NASDAQ · OPT
Healthcare · Biotechnology
$3.41
Up+$0.05 (+1.49%)
Updated Sep 12, 2026, 1:04 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
OPT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning OPT.
OPT research
Company profile and research snapshot.
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | BELL POTTER SECURITIES | Sell | — |
| Nov 11, 2025 | BELL POTTER SECURITIES | Sell | — |
| Nov 10, 2025 | BELL POTTER SECURITIES | Sell | — |
| Sep 4, 2025 | BELL POTTER SECURITIES | Sell | — |
| Sep 3, 2025 | BELL POTTER SECURITIES | Sell | — |
No generated briefing is available yet.
defenseworld.net · Nov 18, 2025
Opthea Limited Unsponsored ADR (NASDAQ: OPT - Get Free Report) rose 7.2% on Monday. The company traded as high as $3.48 and last traded at $3.41. Approximately 3,000 shares traded hands during trading, The stock had previously closed at $3.18. Analyst Upgrades and Downgrades Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OPT.
No results
No recent SID articles mention OPT.
